

		Quarter Ended			Year Ended	
Sr. No.		31 March	31 December	31 March	31 March	31 March
	Particulars	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		2018	2017	2017	2018	2017
1	Segment revenue					
	a. Pharmaceuticals	123774	110073	80847	401679	311665
	b. Life Sciences Ingredients	96981	92574	78384	337239	271432
	c. Drug Discovery Solutions	4694	4485	5130	17723	18241
	Total	225449	207132	164361	756641	601338
	Less : Intersegment revenue	253	356	219	860	706
	Total revenue from operations	225196	206776	164142	755781	600632
	a. Pharmaceuticals	123774	110073	80847	401661	311665
	b. Life Sciences Ingredients	96751	92245	78196	336489	270762
	c. Drug Discovery Solutions	4671	4458	5099	17631	18205
	Total	225196	206776	164142	755781	600632
2	Segment results (profit+)/loss(-) before tax, exceptional Items and Interest from each segment)					
	a. Pharmaceuticals	14155	17701	16566	66164	78536
	b. Life Sciences Ingredients	16589	18505	9573	54814	35170
	■ Drue Discovery Solutions	795	65	236	806	1263
	Total	31539	36271	26375	121784	114969
	Less : i Interest (Finance costs)	7248	7706	8019	28428	34111
	ii Exceptional items and un-allocable expenditure (net of un-allocable income)	1635	2447	2346	7448	7094
	Profit before tax	22656	26118	16010	85908	73764
3	Segment assets					
	a. Pharmaceuticals	617084	607962	586963	617084	586963
	b. Life Sciences Ingredients	293088	290172	260353	293088	260353
	c. Drug Discovery Solutions	15938	17844	18007	15938	18007
	d Unallocable corDorate assets (excluding deferred tax assets)	19607	20758	24552	19607	24552
	Total Segment assets	945717	936736	889875	945717	889875
4	Segment liabilities					
	a. Pharmaceuticals	63034	58960	44878	63034	44878
	b. Life Sciences Ingredients	86811	77608	60289	86811	60289
	c. Drug Discovery Solutions	3372	3341	3018	3372	3018
	d Unallocable corporate liabilities (excluding borrowings and deferred tax liabilities)	41849	36322	33846	41849	33846
	Total Segment liabilities	195066	176231	142031	195066	142031
5	Capital employed (Segment assets less Segment liabilities)					

	a. Pharmaceuticals	554050	549002	542085	554050	542085
	b. Life Sciences Ingredients	206277	212564	200064	206277	200064
	c Drug Discovery Solutions	12566	14503	14989	12566	14989
	d. Unallocable corporate assets less liabilities	(22242)	(15564)	(9294)	(22242)	(9294)
	Total Capital employed	750651	760505	747844	750651	747844